Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma
Do patients and doctors treatment aspirations align? KCCure survey – part A
Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy
Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype
EAU 2024: Bladder cancer latest
Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer
Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Optimising multiple myeloma care in Latin America
Global trends and inequalities in breast cancer survival and care
Multiple myeloma in a resource constrained setting